Sanofi Wins US Approval for Therapy That Delays Progression of Type 1 Diabetes
The United States Food and Drug Administration granted accelerated approval to Sanofi's Tzield, a monoclonal antibody treatment designed to delay the progression of type 1 diabetes in children and adolescents.